Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Core Insights - Ardelyx, Inc. has appointed Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025, bringing over 30 years of experience in corporate finance and strategic planning [1][2] - Hohenleitner previously served as CFO for Johnson & Johnson's Innovative Medicine North America, overseeing financial strategies for a $36 billion business [1][2] - The company aims to leverage Hohenleitner's expertise to enhance its commercial success and pursue growth opportunities [2] Company Overview - Ardelyx focuses on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [5] - The company has two approved commercial products in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [5] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [5] Leadership Transition - Hohenleitner will take over the CFO role following the completion of Ardelyx's Q3 2025 financial reporting [4] - Justin Renz, the current Chief Financial and Operations Officer, will remain in his position until the filing of the Quarterly Report on Form 10-Q [4] Professional Background - Hohenleitner is a Certified Public Accountant and Certified Management Accountant, holding a Bachelor of Science in Accounting and an MBA [3] - She has been recognized as a Top 25 CFO in Biotech by Business & Investing [3]